Hepatitis B Treatment Market
Hepatitis B is also known serum hepatitis which is an infectious disease of the liver caused by Hepatitis B virus HBV. Hepatitis B is classified into two types namely, acute and chronic. In this condition, the virus interferes with the hepatocytes and the liver became inflamed. HepatitisB is commonly caused through parenteral contacts such as blood, body fluids, and sexual intercourse. Hepatitis B virus is unable to cross the skin or mucous membrane. People with Lymph proliferative disease, Acquired Immuno Deficiency Syndrome AIDS, and people treated with immunosuppressant drugs and haemodialysis patients are easily develop an infection with HepatitisB Virus. The symptoms of the Hepatitis B do not develop until after a few weeks of exposure. The severity in Hepatitis may cause the cirrhosis, liver failure, and hepatocellular carcinoma HCC. A vaccine is commonly administered to protect people from the infection. Hepatitis B can be prevented by administering the hepatitis B vaccine to newborn babies, avoiding promiscuity and not having multiple sexual partners, and avoiding sharing of injections and razors can also prevent the Hepatitis B infection.
The global Hepatitis B treatment market is expected to grow at a significant CAGR due to increase in the prevalence of Hepatitis B infection. According to the World Health Organization WHO, chronic hepatitis B virus infection occurs in majority of the infants. Rising awareness regarding hepatitis B treatment, increase in the healthcare expenditure, rise in the funding in research and development activities for hepatitis B treatment, and various pipeline products for Hepatitis B treatment might fuel the global hepatitis B treatment market over the forecast period. However, high cost of the hepatitis B treatment and medications, less effectiveness of antiviral drugs against hepatitis B infection might hamper the growth of global hepatitis B treatment market over the forecast period.
Hepatitis B treatment market segmented on the basis of drug class, route 0f administration, and distribution channel.
Get free sample of Global Hepatitis B Treatment Market Report here – https://www.planetmarketreports.com/report-sample/hepatitis-b-treatment-market-7643
Based on drug class, hepatitis B treatment market has been segmented into the following:
- Chemo Therapy
- Immunosuppressant Therapy
- Nucleoside Analogue
Based on route of administration, hepatitis B treatment market has been segmented into the following:
Based on distribution channel, hepatitis B treatment market has been segmented into the following:
- Hospital Pharmacies
- Retail Pharmacies
To enquire about the report more, click here – https://www.planetmarketreports.com/enquire-now/hepatitis-b-treatment-market-7643
Geographically, hepatitis B treatment market is in growing stage, as various government organizations are initiating awareness programs to prevent the hepatitis B infection. Increase in the prevalence of hepatitis B infection and liver cirrhosis might fuel the hepatitis B treatment market. According to the World Health Organization, there are currently 240 million chronic carriers of hepatitis B virus in which approximately 15–25% of carriers will develop cirrhosis, hepatocellular carcinoma HCC, or liver decompensation, and 780,000 will die each year as a result of their infection. Acquisitions and mergers, collaborations, launching of new products, increase in research and development activities, and approvals for new products from various drug regulatory bodies such as U.S. Food and Drug Administration are some strategies followed by various companies to increase their share in global hepatitis b treatment market. For instance, in September 2013, Roche and Inovio Pharmaceuticals collaborated on research, development, and commercialization of Inovio’s highlyoptimized, multiantigen DNA immunotherapies targeting hepatitis B and prostate cancer. Similarly, in July 2015, Benitec Biopharma and Biomics Biotechnologies are announced that Benitec has acquired the full rights to the preclinical ddRNAibased hepatitis B HBV therapeutic program, Hepbarna, which was previously under development as a joint venture between the two companies. In addition, in October 2010, U.S. Food and Drug Administration approved the Baraclude Entecavir for hepatitis B treatment with the decompensated liver disease in adults manufactured by Bristol Myers Squibb. Moreover, various drugs for the hepatitis B treatment in the pipeline also expected to propel the hepatitis B treatment market over the forecast period.
Geographically, the hepatitis B treatment market has been segmented into following regions Viz. North America, Europe, AsiaPacific, Latin America, and Middle East & Africa. North America is expected to hold a dominant share in hepatitis B market owing to increase In the prevalence of hepatitis B infection according to Centres for Disease Prevention and Control CDC, approximately 1.4 Million patients in the United States are chronically infected with hepatitis B Virus, rise in the awareness towards the use of noveltechnologies and products for hepatitis B treatment, and increase in the research and development activities are the key factors bolster the hepatitis B treatment market in North America region. Europe holds a key share in hepatitis B treatment market owing to increase in the prevalence of hepatitis B infection in Russia, the prevalence rate is approximately 3712 cases per 100,000 people, rise in the geriatric population, change in the lifestyle, and increase in the research and development activities might boost the hepatitis B treatment market in Europe region. Asian Pacific is a key region for hepatitis b treatment market attributed to increase in the prevalence of hepatitis B infection in China, there are 7420 prevalent cases per 100,000 people, rise in the population in Asia Pacific region, and increase in the healthcare infrastructure and healthcare expenditure. Middle East & Africa region expected to exhibit significant growth due to highest prevalence of global hepatitis B infection which is approximately 10,000 prevalent cases per 100,000 people.
Some of the players in hepatitis B treatment market are F. Hoffmann La Roche Ltd. Switzerland, GlaxoSmithKline, plc. U.K., BristolMyers Squibb U.S, Novartis AG Switzerland, Merck and Co U.S, Novira Therapeutics Inc. U.S., Johnson & Johnson U.S., Inovio Pharmaceuticals Inc. U.S., Benitec biopharma Ltd. Australia, Gilead Sciences U.S., Cipla Inc. India, and Biomics biotechnologies China to name a few.
In January 2018, Gilead Sciences, Inc announced that the European Commission granted marketing authorization for Vemlidy tenofovir alafenamide, TAF for the treatment of chronic hepatitis B virus HBV infection in adults and adolescents aged 12 years and older with body weight at least 35 kg
In December 2017, Cipla received an approval from American health regulator to market Entecavir tablets used in the treatment of HBV infection.
To Browse Similar Reports @ https://www.planetmarketreports.com/category/pharmaceutical-and-healthcare
About Us: –
Planet Market Reports gives statistical surveying reports to businesses, people and associations with a goal of helping them in their decision-making process. We have huge database of market research reports & company profiles across globe. We associated with global market research a publisher who has a wide range of research specialists & industry experts which provides you deeper penetration of market research industry.
We have statistical surveying reports from number of top publishers and update our reports collections on daily basis with most recent research data to furnish our customers with the moment online access to our database. With access to this database, our customers will be able to benefit from expert insights on worldwide businesses, items, and market patterns. We help you in your buy choice by mapping your data needs with our immense accumulation of reports.
Name: Ronald James
Organization: Planet Market Reports